Research in Clinical Dermatology

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.
Reach Us +441518081136

Opinion Article - Research in Clinical Dermatology (2025) Volume 8, Issue 1

Evaluating the Safety and Long-Term Outcomes of Phototherapy in Dermatological Disorders

Sonya Peebles *

St John's Institute of Dermatology, King's College London, UK

*Corresponding Author:
Sonya Peebles
St John's Institute of Dermatology, King's College London, UK
E-mail: sonya.peebles@nhs.net

Received: 2-Jan-2025, Manuscript No. aarcd-25-157507; Editor assigned: 4-Jan-2025, PreQC No. aarcd-25-157507 (PQ) Reviewed:17-Jan-2025, QC No. aarcd-25-157507Revised:24-Jan-2025, Manuscript No. aarcd-25-157507; Published:31-Jan-2025, DOI: 10.35841/aarcd- 8.1.246

Citation: Peebles S. Evaluating the safety and long-term outcomes of phototherapy in dermatological disorders. Res Clin Dermatol. 2025;8(1):246

Visit for more related articles at Research in Clinical Dermatology

Introduction

Phototherapy has emerged as a cornerstone in the management of various dermatological disorders, including psoriasis, eczema, vitiligo, and cutaneous T-cell lymphoma. Utilizing ultraviolet (UV) light, primarily UVA and UVB wavelengths, phototherapy offers an effective, non-invasive treatment modality for patients who may not respond well to topical or systemic therapies. However, concerns regarding its safety profile and long-term effects have persisted, raising essential questions about its risk-benefit balance in chronic dermatological care [1].

Phototherapy works by delivering controlled doses of ultraviolet light to the skin, modulating the immune response and reducing inflammatory cytokines. UVB therapy, especially narrowband UVB (NB-UVB), directly targets the epidermal layer and is particularly effective in treating psoriasis and vitiligo. On the other hand, PUVA (psoralen combined with UVA) therapy involves sensitizing the skin with psoralen, enhancing the therapeutic effects of UVA light. These mechanisms reduce cell proliferation, alter cytokine expression, and suppress T-cell activity, leading to symptomatic relief [2].

The most common indications for phototherapy include chronic plaque psoriasis, atopic dermatitis, vitiligo, and mycosis fungoides. NB-UVB is preferred for its efficacy and better safety profile, while PUVA therapy is often reserved for severe or resistant cases. Despite its widespread use, treatment protocols must be carefully tailored to individual patients to minimize risks and optimize therapeutic outcomes [3].

Short-term adverse effects of phototherapy are relatively well-documented. Common side effects include erythema (skin redness), pruritus (itching), xerosis (dry skin), and occasional blistering. Patients undergoing PUVA therapy may also experience nausea and photosensitivity reactions due to psoralen intake. These side effects are generally transient and manageable through dose adjustments and supportive care [4].

The primary long-term concern associated with phototherapy is an increased risk of skin cancer, particularly squamous cell carcinoma (SCC) and basal cell carcinoma (BCC). Studies suggest that PUVA carries a higher risk compared to NB-UVB due to the combined effect of psoralen and UVA radiation. Prolonged exposure to UV radiation may also accelerate photoaging, characterized by skin wrinkling, pigmentary changes, and loss of elasticity [5].

PUVA therapy, especially with higher cumulative doses, has been linked to a significant increase in SCC risk. In contrast, NB-UVB is considered relatively safer, with no strong evidence linking it to increased melanoma risk. Nevertheless, dermatologists must carefully monitor patients receiving long-term phototherapy, especially those with fair skin, a history of skin cancer, or excessive UV exposure from other sources [6].

To ensure patient safety, routine skin examinations and cumulative dose tracking are critical components of phototherapy protocols. Protective measures, including eye shielding and avoidance of unnecessary sun exposure, are essential. For PUVA therapy, liver function tests and regular ophthalmic assessments are recommended to prevent psoralen-induced complications [7].

Not all patients are suitable candidates for phototherapy. Contraindications include a history of photosensitivity disorders (e.g., lupus erythematosus), active skin cancer, or severe liver dysfunction (for PUVA). Patient education is equally vital, ensuring they understand potential risks, adherence to treatment schedules, and protective measures during therapy [8].

Beyond clinical efficacy, phototherapy has demonstrated significant improvements in patients' quality of life. Relief from chronic symptoms like itching, pain, and visible skin lesions often leads to better psychological well-being and enhanced social confidence. Long-term remission rates with phototherapy are also encouraging, particularly in psoriasis and vitiligo patients [9].

Recent advancements, such as targeted phototherapy devices and excimer lasers, allow for more precise treatment of localized lesions, minimizing exposure to unaffected skin. Research into novel photosensitizers and combination therapies also holds promise for improving efficacy and reducing adverse effects [10].

Conclusion

Phototherapy continues to be a valuable tool in the dermatological arsenal, offering effective treatment for a range of chronic skin disorders. Despite concerns regarding long-term risks, especially skin cancer, the benefits often outweigh the potential drawbacks when protocols are carefully followed. Ongoing research and technological advancements are expected to further refine phototherapy techniques, making them even safer and more effective for future patients.

References

  1. Patrizi A, Raone B, Ravaioli GM. Safety and efficacy of phototherapy in the management of eczema. Ultraviolet Light in Human Health, Diseases and Environment. 2017:319-31.

    2. Indexed at, Google Scholar, Cross Ref

  2. Patrizi A, Raone B, Ravaioli GM. Management of atopic dermatitis: Safety and efficacy of phototherapy. Clin Cosmet Investig Dermatol. 2015:511-20.

    3. Indexed at, Google Scholar, Cross Ref

  3. Bae JM, Ju HJ, Lee RW, et al. Evaluation for skin cancer and precancer in patients with vitiligo treated with long-term narrowband UV-B phototherapy. JAMA Dermatol. 2020;156(5):529-37.

    4. Indexed at, Google Scholar, Cross Ref

  4. Seccombe E, Wynne MD, Clancy C, et al. A retrospective review of phototherapy in children, at a tertiary paediatric dermatology unit. Photodermatol Photoimmunol Photomed. 2021;37(1):34-8.

    5. Indexed at, Google Scholar, Cross Ref

  5. Meduri NB, Vandergriff T, Rasmussen H, et al. Phototherapy in the management of atopic dermatitis: A systematic review. Photodermatol Photoimmunol Photomed. 2007;23(4):106-12.

    6. Indexed at, Google Scholar, Cross Ref

  6. Ablon G. Phototherapy with light emitting diodes: Treating a broad range of medical and aesthetic conditions in dermatology. J Clin Aesthet Dermatol. 2018;11(2):21.

    7. Indexed at, Google Scholar

  7. Pfaff S, Liebmann J, Born M, et al. Prospective randomized long-term study on the efficacy and safety of UV-free blue light for treating mild psoriasis vulgaris. Dermatol. 2015;231(1):24-34.

    8. Indexed at, Google Scholar, Cross Ref

  8. Coelho MM, Apetato M. The dark side of the light: Phototherapy adverse effects. Clin Dermatol. 2016;34(5):556-62.

    9. Indexed at, Google Scholar, Cross Ref

  9. Davis DM, Drucker AM, Alikhan A, et al. Guidelines of care for the management of atopic dermatitis in adults with phototherapy and systemic therapies. J Am Acad Dermatol. 2024;90(2):e43-56.

    10. Indexed at, Google Scholar, Cross Ref

  10. Krenitsky A, Ghamrawi RI, Feldman SR. Phototherapy: A review and update of treatment options in dermatology. Curr Dermatol Rep. 2020;9:10-21.

    11. Indexed at, Google Scholar, Cross Ref

Get the App